Approval to Covaxin for children aged between 2-18 years awaited after evaluation of data

Published by
WEB DESK

After the evaluation of data Covaxin is yet to get approval by the Drugs Controller General of India (DCGI) for children between 2-18 years old, according to official sources.
   
Bharat Biotech, the manufacturer of Covaxin, has submitted data for clinical trials in the age group of 2-18 years to Central Drugs Standard Control Organisation (CDSCO).

The data has been thoroughly reviewed by the CDSCO and Subject Experts Committee and has provided their positive recommendations. (ANI)
  
                    
 

Share
Leave a Comment